Results 251 to 260 of about 64,225 (335)

DeepSeek for healthcare: do no harm? [PDF]

AI Ethics
Anibal J, Bedrick S, Nguyen H, Gunkel J, Huth H, Le T, Salvi Cruz S, Hazen L, Wood BJ.   +8 more
europepmc   +1 more source

Understanding Inequality Within a Personalised System of Disability Support: Australian Children With Disabilities' Unmet Support Needs

Australian Journal of Social Issues, EarlyView.
ABSTRACT Disability support has shifted towards models of personalised care, which critics argue may contribute to increased inequalities. There is limited systematic evidence investigating inequalities in support among children with disabilities. To investigate inequalities in support, a survey of parents of children with disabilities aged 2–17 was ...
Martin O'Flaherty, Jessica Hill, Jennifer Smith‐Merry   +2 more
wiley   +1 more source

The Essential Elements Doctrine in Patent Infringement: Free World and Whirlpool in Light of Kirin-Amgen [PDF]

, 2011
Norman Siebrasse
openalex  

ArtiFacts: The UCI Total Knee Prosthesis. [PDF]

Clin Orthop Relat Res
Hawk AJ.
europepmc   +1 more source

Disruption of the Blood–Brain Barrier Predicts Progression of Cerebral Small Vessel Disease White Matter Hyperintensities

Annals of Neurology, EarlyView.
Objective The objective of this study was to test if blood–brain barrier (BBB) disruption, detected using dynamic susceptibility contrast (DSC) imaging, would predict progression of white matter hyperintensities (WMHs) over the subsequent year in patients with chronic cerebrovascular disease. Methods The study included patients with a history of stroke
Richard Leigh, Kyle C. Kern, Nae‐Yuh Wang, Rebecca F. Gottesman, Clinton B. Wright   +4 more
wiley   +1 more source

Amyotrophic Lateral Sclerosis and Frontotemporal Dementia Have Distinct Prediagnostic Blood Biochemical Profiles

Annals of Neurology, EarlyView.
Objective Identifying modifiable factors influencing amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) risk is important for prevention. Blood biomarkers, particularly cholesterol, have been associated with neurodegenerative risk, but findings in ALS are inconsistent, and data on FTD are limited.
Christos V. Chalitsios, Jiali Gao, Carol A.C. Coupland, Julia Hippisley Cox, Martin R. Turner, Alexander G. Thompson   +5 more
wiley   +1 more source

AI in Combating Cyber Threats to Indian Pharmaceutical Intellectual Property: Legal Perspectives.

J Pharm Bioallied Sci
Sharma G, Variath AG, Medhoo P, Srivastava A, Rathore S, Rathore D.   +5 more
europepmc   +1 more source

Different routes the same destination: a comparative study of antitrust regulation for pharmaceutical industry in the United States and China. [PDF]

Front Pharmacol
Weng J, Liu N.
europepmc   +1 more source

Real‐World Effectiveness of Switching to Oral or Infusion Versus Injectable Disease‐Modifying Therapy in Pediatric Multiple Sclerosis

Annals of Neurology, EarlyView.
Objective To assess real‐world effectiveness of switching disease‐modifying therapy (DMT) in pediatric multiple sclerosis (MS) and clinically isolated syndrome (CIS) initially treated with platform injectables on disease activity. Methods Of 2615 pediatric‐onset demyelinating disease patients at 12 clinics in the United States (US) Network of Pediatric
Aaron W. Abrams, Michael Waltz, T. Charles Casper, Gregory Aaen, Leslie A. Benson, Eva‐Chava M. Bernfeld, Leigh E. Charvet, Tanuja Chitnis, Carla Francisco, Mark P. Gorman, Jennifer S. Graves, Lauren Krupp, Kimberly O'Neill, Timothy E. Lotze, Soe Mar, Jayne Ness, Mary Rensel, Moses Rodriguez, John Rose, Alice Rutatangwa, Teri Schreiner, Nikita Shukla, Jan‐Mendelt Tillema, Bianca Weinstock‐Guttman, Yolanda Wheeler, Emmanuelle Waubant, Kristen M. Krysko, on behalf of the US Network of Pediatric MS Centers   +27 more
wiley   +1 more source

Cross-Border IP Infringement: Patents

, 2012
Marketa Trimble
openalex   +1 more source